EAGLE-1 Phase III Data Show Potential for Gepotidacin as a New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea (GC) Amid Growing Resistance to Existing Treatments
17 April 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
Susceptibility Testing In Neisseria Gonorrhoeae (STING) Study, Assessing the Performance of a New Rapid Test for Gonorrhoea Antibiotic Resistance, in a Cohort of 100 Culture Positive Neisseria Gonorrhoeae Infections
Conditions: Diagnosis; Gonorrhea; Resistance Bacterial Sponsors: SpeeDx Pty Ltd; Biomedical Advanced Research and Development Authority; Wellcome Trust; German Federal Ministry of Education and Research; Australian Research Council Research Hub to Combat Antimicrobial Resistance Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
GSK Announces Positive Headline Results from EAGLE-1 Phase III Trial for Gepotidacin in Uncomplicated Urogenital Gonorrhoea (GC)
London, UK 26 February 2024 GSK plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea
Conditions: Gonorrhea Interventions: Drug: Cefixime; Drug: Doxycyclin; Drug: Ceftriaxon; Drug: Azithromycin Sponsors: Bulovka Hospital; Örebro University, Sweden Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Cefixime 800 mg Plus Doxycycline 100 mg b.i.d. for 7 Days Compared to Ceftriaxone 1 g Plus Azithromycin 2 g for Treatment of Urogenital, Rectal and Pharyngeal Gonorrhoea
Conditions: Gonorrhea Interventions: Drug: Cefixime; Drug: Doxycyclin; Drug: Ceftriaxon; Drug: Azithromycin Sponsors: Bulovka Hospital; Örebro University, Sweden Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
GSK Receives US FDA Fast Track Designation for Investigational Vaccine Against Gonorrhoea
Fast Track designation accelerates the vaccine candidate’s path to US FDA submission for the prevention of Neisseria gonorrhoeae infection
Gonorrhoea is the second most prevalent bacterial sexually transmitted infection worldwide with an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 27, 2023 Category: Pharmaceuticals Source Type: clinical trials
The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Conditions: Sexually Transmitted Diseases, Bacterial; Antibiotic Resistant Infection Intervention: Sponsors: Cwm Taf University Health Board (NHS); Cardiff University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2022 Category: Research Source Type: clinical trials
